Copy Link Print Information

Faricimab

(別名: RG7716; RO-6867461)
カスタマーレビュー

Based on 1 Customer Validation

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 97.97%
  • CAS 番号: 1607793-29-2
  • 分子量:146.16 kDa
  • 保管条件:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Faricimab
  • Experimental Validation Results for Faricimab
  • Experimental Validation Results for Faricimab
  • Experimental Validation Results for Faricimab
  • Faricimab Chemical Structure
    Faricimab 構造式
CAS 番号: 1607793-29-2
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Faricimab おすすめ製品:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
Top Publications Citing

Use of MCE Products

VEGFR アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover

  • 1/16

    Immobilized Faricimab can bind VEGF165 Protein, Human.The EC50 for this effect is 3.418 ng/mL.

  • 1/16

    Immobilized Faricimab can bind Human Angiopoietin-2/ANGPT2 Protein (His Tag).The EC50 for this effect is 4.10 ng/mL.

  • 1/16

    Flow cytometric analysis of 1X106 HeLa cells with Faricimab (HY-P99116, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.

  • Faricimab Chemical Structure
    1/16
  • Faricimab
  • Immobilized Faricimab can bind VEGF165 Protein, Human.The EC50 for this effect is 3.418 ng/mL.
  • Immobilized Faricimab can bind Human Angiopoietin-2/ANGPT2 Protein (His Tag).The EC50 for this effect is 4.10 ng/mL.
  • Flow cytometric analysis of 1X106 HeLa cells with Faricimab (HY-P99116, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
  • IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover